
chikungunya is a mosquito-borne virus that causes sudden fever and intense joint pain. Most people recover in about a week, but some have joint pain that lingers for months or even years. There is no specific antiviral treatment. Care is supportive: rest, fluids, and acetaminophen for pain and fever. Vaccines exist and may be recommended for some travelers. Prevention focuses on avoiding mosquito bites and reducing standing water where mosquitoes breed.
This guide pulls together recent public information about chikungunya, including symptoms, where it’s found, vaccine status, U.S. case trends, and practical steps you can take at home and when you travel.
chikungunya (often shortened to CHIKV for the virus) spreads to people through the bites of infected Aedes mosquitoes, mainly Aedes aegypti and Aedes albopictus. It is not spread by casual contact, coughing, sneezing, or saliva. Rare spread can occur through blood exposure (for example, in a lab or during certain medical procedures).
If you are infected, it’s important to avoid new mosquito bites during the first week of illness. During that time, the virus is present in your blood at high levels. A mosquito that bites you can pick up the virus and then spread it to other people.
Once limited to parts of Africa and Asia, chikungunya is now global. Risk exists in the Americas, Africa, Asia, and Europe, and on islands in the Caribbean and the Indian and Pacific Oceans. More than 100 countries have reported cases in recent years.
In the United States, locally acquired chikungunya cases have not been reported in U.S. states or territories since 2019. Most U.S. cases are linked to travel to areas with ongoing transmission. In 2025 (through September 30), U.S. states reported zero locally acquired cases and 88 travel-associated cases.
Most people develop symptoms 3-7 days after an infected mosquito bite. The hallmark is sudden high fever with severe joint pain. Many describe the pain as “bending” or “stooping” pain.
Other symptoms can include:
Most people feel better within 7-10 days. For a significant share, joint and muscle pain can persist for months or even years. Severe disease and death are rare, but they can occur.
Higher-risk groups for severe outcomes include:
After recovery, people appear to have protection against future infections.
Tell a clinician about recent travel if you develop a sudden fever and joint pain. Early in illness (first week), a PCR test can detect the virus in blood. After the first week, antibody tests can help confirm past infection.
There is no specific antiviral for chikungunya. Treatment is supportive:
For long-lasting joint pain, clinicians may consider treatments used for inflammatory joint conditions. Always follow medical advice for your situation.
Two vaccines are available in the United States:
Who should consider vaccination?
Vaccination may be recommended for travelers to areas with an active chikungunya outbreak, and for certain lab workers with potential exposure. It may also be considered for longer stays (for example, six months or more) in places with elevated risk for U.S. travelers, even if there is no declared outbreak. Discuss your itinerary, timing, and health conditions with a travel clinic or healthcare professional.
When planning travel, check for:
Who should reconsider travel during outbreaks?
If you choose to travel, talk with your clinician about vaccination (where indicated) and bite-prevention steps.
Mosquitoes that spread chikungunya can bite day and night. Protect yourself at home and on the road.
Use effective repellents
Dress for protection
Control mosquitoes around you
If you’re sick
These trends can change. Always check current notices before you travel.
Outdoor mosquito control comes first; indoors you still need fast, consistent hygiene. AeroClave adds a reliable indoor layer to your Chikungunya strategy by killing mosquitos using EPA-registered Vital Oxide. Choose the setup that fits your use case from the Hydra multi room unit to our flagship RDS 3110 Model we have a solution that fits your needs.
If you manage stations, clinics, classrooms, offices, or fleets, we’ll map your spaces, train your team, and get you running quick turnarounds that keep operations ready through peak Chikungunya. Tell us your facility type, number of rooms/vehicles, and goals (faster turnarounds, audit-ready records, surge readiness). Contact AeroClave today to learn how our advanced decontamination systems can protect your team and community.

In conclusion, chikungunya is a mosquito-borne viral illness that causes sudden fever and significant joint pain, with most people recovering in about a week but some experiencing lingering symptoms for months or years. It spreads through Aedes mosquitoes (not casual person-to-person contact), so the most effective protection is preventing bites: use EPA-registered repellents, wear long sleeves and pants, treat clothing with permethrin, and remove standing water around homes and facilities. There’s no specific antiviral treatment-care is supportive-and testing (PCR early, serology later) helps confirm the diagnosis. Vaccination may be recommended for certain travelers and lab workers, with current guidance prioritizing non-live options where appropriate. In the United States, there have been no locally acquired cases reported since 2019, but travel-related infections continue, so check outbreak notices before trips and avoid mosquito exposure during the first week of illness to prevent onward spread. Pair strong vector control with consistent environmental hygiene to reduce overall risk in homes, schools, clinics, and response vehicles.
Contact AeroClave today to learn how our advanced decontamination systems can protect your team and community.
It’s a virus spread by mosquitoes that causes high fever and intense joint pain. Most people recover in a week, but some have long-lasting joint pain.
From the bite of an infected Aedes mosquito. It’s not spread by casual person-to-person contact.
Yes. VIMKUNYA (ages 12+) is a single-dose, non-live vaccine. The U.S. license for the live-attenuated IXCHIQ vaccine was suspended on August 22, 2025. Ask a clinician if vaccination is right for your trip.
AeroClave provides advanced decontamination solutions that help organizations strengthen infection control practices.
Common users include emergency services, healthcare facilities, schools, government agencies, and other organizations that need reliable environmental decontamination.
No. They are used alongside routine cleaning and public health guidance. Follow local health authorities for mosquito control and travel recommendations.